Boston, MA, 07/12/2013 (nysepost) – Trius Therapeutics, Inc. (NASDAQ:TSRX), a biopharmaceutical research and development company, made a presentation at the JMP Securities Healthcare conference. The meeting included the presence of a wide range of investors like venture capitalists, angel and institutional investors, interested specifically in the pharmaceutical sector and was held on July 09, 2013 in St. Regis Hotel, New York.
TSRX has been mainly focusing on the research, development and commercialization of treatment therapies and drugs for different kinds of diseases. The company entered into a cooperative agreement on research and development with the Lawrence Livermore National Security LLC. This agreement between the two partners enables cooperation in the research and development of gram-negative bio defense pathogens. Furthermore, TSRX entered into a license agreement with Dong-A Pharmaceutical Co. Ltd aiming at the development and sales of Torezolid Phosphate in the markets outside Korea. The effectiveness of presentations made by the pharmaceutical company at the JMP Securities Healthcare conference caused the share price of the company to soar by around 20% in two days, to touch new peaks in the 52-week high price levels for the stock.
Trius Therapeutics, Inc. (NASDAQ:TSRX) closed at $9.84 on Thursday, recording an increase of 9.58% in the share price for the day. The stock price fluctuated from a low value of $8.97 to a high one of $9.87 per share. The company currently has a 52-week low of $4.41 and a 52-week high of $9.87 per share. Trius Therapeutics currently has 47.87 million outstanding shares in the market with institutional ownership of 69% of its total equity capital. Trading volume stood at 3.51 million shares on Thursday, with an average one for Trius Therapeutics at 1.01 million shares per day.